Biontech SE Raises Fy2026 Revenue Guidance Midpoint To €1.7–1.9 Billion

What happened

BioNTech reported third-quarter earnings per share of €0.73, revenue of €1,289.2 million and net income of €184.5 million. The company raised its full-year 2026 revenue guidance midpoint to €1.7–1.9 billion and entered a share repurchase program for up to $1 billion in ADSs until May 2027.

Confirmed

Global impact / market context

A higher revenue outlook signals management expects more sales than previously planned, which can support funding for research and operations. The buyback uses company cash to repurchase its own shares, which can reduce shares outstanding and support the stock, while the year-to-date adjusted net loss shows profitability remains uneven.

Analyst inference

Investors are weighing improving quarterly profit against a year-to-date adjusted net loss of €615.90 million, a mixed signal for earnings stability. The buyback authorizes up to $1 billion, and repurchases so far total $463.3 million, leaving room for further purchases that could influence share count and investor positioning.

Analyst inference

What to watch

1. Watch whether full-year 2026 revenue lands within the raised €1.7–1.9 billion guidance range, since actual results will show whether the improved outlook is met. Confirmed
2. The company plans to keep repurchasing up to $1 billion in ADSs until May 2027, so track how much of that authorization is used and at what prices. Proposed
3. Monitor whether quarterly profit continues and the year-to-date adjusted net loss narrows, which would indicate steadier earnings and could affect how investors value the shares. Analyst inference

Evidence

• Original source link unavailable